|
| Press Releases |
|
 |
|
| Sunday, September 26, 2021 |
|
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
| Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
| Wednesday, September 15, 2021 |
|
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
| On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
| Thursday, August 19, 2021 |
|
|
Hua Medicine Announces 2021 Interim Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
| Friday, April 23, 2021 |
|
|
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). more info >> |
|
| Friday, March 19, 2021 |
|
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
| Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
| Friday, December 18, 2020 |
|
|
Hua Medicine Completes Registration Phase III Trials; Announces 52-Week Result for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: more info >> |
|
| Wednesday, October 14, 2020 |
|
|
Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin |
Hua Medicine (the "Company", Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder ("MAH") system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau.
more info >> |
|
| Monday, August 17, 2020 |
|
|
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China |
| Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. more info >> |
|
| Wednesday, July 1, 2020 |
|
|
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin |
| Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. more info >> |
|
| Thursday, June 18, 2020 |
|
|
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301) more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
CheckDot Announces the Launch of Its Platform Which Will Save Crypto Industry
Jan 20, 2022 13:00 HKT/SGT
|
|
|
Honda Invests in U.S.-based Helm.ai to Strengthen its Software Technology Development
Jan 20, 2022 13:04 JST
|
|
|
Interview: What You Need to Know about Cardano (ADA) in 2022 
Jan 20, 2022 11:00 HKT/SGT
|
|
|
NexBloc and Arcade Network Partner to Bring Blockchain Domains to Gaming in the Metaverse
Jan 20, 2022 09:28 HKT/SGT
|
|
|
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
Jan 20, 2022 9:56 JST
|
|
|
TopFlower Is Introducing a Perfect NFT Farming Game
Jan 19, 2022 18:00 HKT/SGT
|
|
|
MyTVchain Announces Closure of $880k Private Seed Round
Jan 19, 2022 18:00 HKT/SGT
|
|
|
The Crypto Universe Now Has Savage Meme Token: AngryKitty Launches to Set New Rules on the Digital Playground
Jan 19, 2022 18:00 HKT/SGT
|
|
|
CEFC Financial was Granted the Exclusive Right of Use of the Intellectual Property Right of Animated Characters by Chengdu Dreamtoys
Jan 19, 2022 16:52 HKT/SGT
|
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
Jan 19, 2022 17:36 JST
|
|
|
Honda and V2X Suisse Consortium to Advance Vehicle-to-Grid Charging Technology in Switzerland
Jan 19, 2022 17:00 JST
|
|
|
Honda Signs Joint Development Agreement with SES, an EV Battery Research and Development Company
Jan 19, 2022 13:01 JST
|
|
|
Spritzer Gives New Life to Bottles as Decorations for Chinese New Year
Jan 19, 2022 12:00 HKT/SGT
|
|
|
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
Jan 19, 2022 10:06 JST
|
|
|
GCBC is Giving Rare NFT Holders a Seat at the Owner's Table
Jan 18, 2022 23:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
